The data can be found at <https://doi.org/10.7910/DVN/PIFXWN>.

Introduction {#sec001}
============

Acute rheumatic fever (ARF) is a multisystemic sequela of a post infection autoimmune reaction due to untreated group A β haemolytic *Streptococcus* (GABHS) pharyngitis and possibly pyoderma \[[@pntd.0008558.ref001],[@pntd.0008558.ref002]\]. The main features of ARF include elevated inflammatory and GABHS serological markers, as well as one or more of carditis, rheumatic arthritis (Rh.A), skin/soft tissue manifestations or chorea. Recurrent episodes of ARF and its associated cardiac inflammation ultimately lead to permanent valvular damage and rheumatic heart disease (RHD) \[[@pntd.0008558.ref002]\]. Molecular mimicry between the GABHS and heart or brain structures underlays the immune responses in ARF, where cross-reactive antibodies and T-cells that react with self-antigens are the effectors of valve or brain tissue damage \[[@pntd.0008558.ref001],[@pntd.0008558.ref003],[@pntd.0008558.ref004]\]. The risk of ARF recurrences increases following the initial episode, although it can be largely prevented by secondary prophylaxis with injectable long-acting penicillin \[benzathine penicillin G (BPG\] every 3--4 weeks \[[@pntd.0008558.ref005],[@pntd.0008558.ref006]\].

ARF and its sequel, RHD are serious but preventable health conditions that can occur in children and young adults. Except for a lingering burden in elderly people, ARF and RHD are virtually disappearing in high-income countries due to improved living conditions and medical care. However, these conditions are not receiving enough attention and are inadequately controlled in most of the low resource countries \[[@pntd.0008558.ref003],[@pntd.0008558.ref007]\]. Apparently, demographic shifts and immigration from low-income to high-income settings might be responsible for a new burden of RHD in regions in which the disease has been eliminated \[[@pntd.0008558.ref008]\]. The disease is prevalent in developing regions that are characterized by impoverished socioeconomic determinants \[[@pntd.0008558.ref003],[@pntd.0008558.ref007]\]. Of concern, the Middle East, the Indian subcontinent, and some areas of Africa and South America, that show over 20 million new cases each year. Globally, 30 million people are currently affected by RHD, with 233,000 directly attributable deaths. This represents 25--40% of all cardiovascular disease and accounts for 25--50% of all cardiac admissions \[[@pntd.0008558.ref009]\].

The pathogenesis of ARF remains enigmatic, and specific treatment is not available. Yet, the prevention of the initial and recurrent attacks is possible with penicillin treatment. In Egypt, the prevalence of RHD has been declining over the past 3 decades and has currently plateaued at \~10/1000 population \[[@pntd.0008558.ref010],[@pntd.0008558.ref011]\]. There are actually 300,000 patients with RHD aged 5 to 15 years of age \[[@pntd.0008558.ref012]\]. These patients require adequate medical care to prevent their progression to severe valvular damage and save their lives. If these patients are neglected, they will require 300,000 open-heart surgeries, which will cost the nation 1.7 billion US\$ dollars.

The National RHD prevention and control program in egypt {#sec002}
--------------------------------------------------------

RHD is a national issue in Egypt and is being given priority by the Egyptian Ministry of Health and Population (MOHP) under the auspices of all the experts and leaders concerned. The national RHD prevention and control program was established in 2006 through the RHD centre in Mahalla El-Koubra province, in collaboration with the WHO-Egypt. It was expanded in 2010--2014 to include 30 RHD primary care centres covering the country and are linked to tertiary-level of care cardiac centres. The ultimate goal is to reduce mortality from RHD and declare Egypt free of ARF by 2030. The program conforms to the international guidelines for the identification and management of pharyngitis, ARF and RHD, which are approached from a variety of angles \[[@pntd.0008558.ref006],[@pntd.0008558.ref008],[@pntd.0008558.ref013],[@pntd.0008558.ref014],[@pntd.0008558.ref015]\]. Guided by the conceptual framework for comprehensive RHD control programs developed by Wyber \[[@pntd.0008558.ref006],[@pntd.0008558.ref016]\], the program structure falls into primordial, primary, secondary and tertiary levels of prevention that prioritize capacity building, raising awareness as well as disease surveillance and management ([Fig 1](#pntd.0008558.g001){ref-type="fig"}).

![Components of the national rheumatic heart disease prevention and control program founded in Egypt in 2006.\
The program follows the conceptual framework for comprehensive RHD control programs. **Footnote of Fig 1:** ARF; acute rheumatic fever, BPG; benzathine penicillin G, HIS; Health Information Systems, REDcap; Research Electronic Data Capture, Rh.A; rheumatic arthritis, RHD; rheumatic heart disease, S. Chorea; Sydenham's Chorea.](pntd.0008558.g001){#pntd.0008558.g001}

The program involves the identification of ARF and RHD among the suspected cases referred to RHD centres. There is no age limit for the screening and the screening materials target primarily at RHD and ARF. For instance, school-age children are screened at school entry by trained physicians using auscultation. Suspected cases are then referred to specialized RHD centres for confirmation by echocardiography. Since mild RHD is asymptomatic, and patients with RHD do not seek health care except at late stages of the disease or when complications develop, the program implements active case identification through large-scale field echocardiography screening campaigns and outreach caravans (community- and school-based) using portable and mobile echocardiography. In addition, screening of pregnant women is performed in antenatal care. As a part of post-operative planning for RHD patients who underwent cardiac surgery, their family members are invited to screening for RHD.

Other components of the program include case registry for the registration of identified rheumatic cases, raising awareness for management of GABHS infection, ARF and RHD through mass media and campaigns which target health care workers, teachers, youth centres, civil societies, clergy, community leaders, and the public at large. A video clip of a folkloric song in local language for children was developed for promoting health message for ARF and RHD prevention. The song was created by the authors and recorded by a famous Egyptian folklore singer to be disseminated through the different media channels and in the daily health education sessions held by the program ([S1 Video](#pntd.0008558.s008){ref-type="supplementary-material"} with English subtitles).

Because the program is run via the Egyptian MOHP, an emphasis is placed on capacity building, both in public health and medical sectors. Hundreds of health care workers are trained to recognize the clinical signs and symptoms of GABHS pharyngitis and to administer proper treatment with one-time BPG injection ([S1 Table](#pntd.0008558.s001){ref-type="supplementary-material"}). Training materials, including clinical guidelines \[[@pntd.0008558.ref015]\], are distributed to health professionals down to the health unit level in which providers are instructed to refer patients with symptoms for formal evaluation with echocardiography at the specialized regional centres. Practical actions are being taken to improve the standard of living in impoverished and disadvantaged regions. Work to strengthen the quality of BPG and collaborative research with Sir. Magdy Jacob Research Centre (United Kingdom) to develop a vaccine for GABHS are underway.

We share in this local experience the epidemiological features of ARF and its sequelae a population with very high disease rates, how accurate was their diagnosis made by health practitioners, and the compliance with the use of BPG, in El--Mahalla RHD centre where the national RHD prevention and control program was first established.

Methods {#sec003}
=======

Ethics statement {#sec004}
----------------

The study was approved by the institutional review board and the ethics committee of the High Institute of Public Health affiliated with Alexandria University, Egypt (ref: 305--2018). The study was conducted in accordance with the international ethical guidelines and of the Declaration of Helsinki \[[@pntd.0008558.ref103]\]. Informed written consent was obtained from each participant after explaining the aim and concerns of the study. Parents, guardians and caregivers provided written consent on behalf of children and those with mental disabilities. Data sheets were coded by number to ensure anonymity and confidentiality of the participants' data.

Study setting and design {#sec005}
------------------------

A cross-sectional study was conducted through the national RHD prevention and control program implemented in El--Mahalla RHD centre. The RHD centre in El--Mahalla was the first established centre to run the RHD program in 2006, owing to the high burden of the ARF/RHD cases identified and refereed there. Starting from 2010, several centres were established in other cities in Egypt until reaching 30 centres in 2014. Unlike the other centres, the program data in El--Mahalla RHD centre covers longer a period of time dating to 2006. The centre is located in Mahalla El-Koubra province, which is one of eight administrative districts of the Gharbia governorate (Northern Egypt) with \~2 million inhabitants \[[@pntd.0008558.ref017]\].

Study period {#sec006}
------------

The study was conducted between 2006 and 2018. Data about the economic burden of RHD at El-Mahalla cardiac centre covered the period 1998--2018.

Study population {#sec007}
----------------

Over the last decade (2006--2018), a total of 17014 suspected ARF and RHD patients were referred to the RHD centre in the El-Mahalla. Those referred for consideration comprised three groups:

i\) anyone with symptoms suggesting ARF/RHD who sought medical advice at El-Mahalla RHD centre after learning about the program from relatives, neighbours, advertisement, media or the program folkloric song, ii) those with known RHD condition as has been tentatively diagnosed in other health care settings and referred to El-Mahalla RHD centre. Interestingly, a large number of this particular group were misguidedly prescribed long term BPG for secondary prophylaxis, without being confirmed as having RHD by echocardiography. Instead, their health care physicians were relying on symptoms suggesting RHD \[breathlessness, dyspnoea on effort in patients with a history of recurrent attacks of sore throat/tonsillitis, joint pain, arthritis\] and the elevated ESR for establishing the diagnosis of RHD. We refer thereafter to this group of patients as "misdiagnoses", iii) school children screened at school entry by school physician. Those suspected to have ARF or RHD are referred to El-Mahalla RHD centre, iv) family members of patients with established RHD who had cardiac surgery. These included a total of 259 RHD patients who were primarily screened through the RHD program in El-Mahalla centre and eventually underwent cardiac surgery for RHD. Their valvular condition was severe and indicated the need for valve replacement cardiac surgery which was done at a tertiary care cardiac centre. After being operated, we invited them to bring their children/household members to check for RHD. The total number of the screened relatives of these 259 RHD patients was 769 family members.

All referred subjects were enrolled in the program and evaluated accordingly. Although the program involves case registry and follow-up of the identified ARF and RHD patients as being undertaken at all RHD centres in Egypt, this report is confined to one-time information gathered at the screening phase. One protocol was applied to all subjects referred to the centre.

Screening and identification of ARF and RHD cases {#sec008}
-------------------------------------------------

Screening of enrolled subjects included history taking, clinical evaluation through general physical examination, auscultation, ECG and echocardiography, and case review by a cardiologist.

Data collection was done through a data collection sheet which included two sections: a) a pre-designed structured interview questionnaire that covered baseline sociodemographic data, history of ARF manifestations and its sequelae, and the use of BPG. According to El-Gilany et al. \[[@pntd.0008558.ref018]\], the socioeconomic status was determined based on the level of education, occupation, income per capita, residency, crowding index (the total number of co-residents per household, excluding the new-born infant, divided by the total number of rooms, excluding the kitchen and bathrooms) \[[@pntd.0008558.ref019]\], and sanitation (presence of safe water supply, electricity, household water closet, sewage disposal, and garbage disposal). Non-adherence to BPG use for secondary prophylaxis for all individuals who have had an initial attack of ARF \[[@pntd.0008558.ref020]\] was defined as patients taking \<80% of the prescribed medication \[[@pntd.0008558.ref021]\]; b) a sheet for the presenting clinical data of each individual including auscultation, ECG and the results of the Doppler echocardiography which is considered the most important criterion for the diagnosis of RHD. For the case diagnosis of ARF, the revised Jones criteria \[[@pntd.0008558.ref015]\] were applied. Arthritis was diagnosed by the presence of swelling, pain, heat in the joints, and limitations in joint movement. Atypical joint involvements \[mono- or oligoarticular, additive, symmetric, involving small joints of the hands and feet, and persistent\] \[[@pntd.0008558.ref022]\] were also considered to avoid under diagnosis. The diagnosis of Sydenham's chorea was based on the exclusion of other causes and forms of chorea. In some cases, Sydenham's chorea was found in presence of arthritis and/or carditis. Normal peers were defined as screened individuals who were found free of any rheumatic condition (those who were referred and were not diagnosed with ARF or its complications, normal family members of cardiac surgery patients who were screened and found free of ARF or its sequelae, and individuals with prior misdiagnoses).

Laboratory investigations {#sec009}
-------------------------

Indicators of inflammation including the erythrocyte sedimentation rate (ESR), Antistreptolysin-O titre (ASOT), and C-reactive protein (CRP) were done only for acute cases, whether cases of carditis or arthritis. A value above 20 mmHg/first hour for ESR was considered elevated. ASOT greater than 200 IU was considered abnormal and an evidence of a recent GABS infection \[[@pntd.0008558.ref007]\]. No serial ASOT measurements were performed because it was not feasible to obtain acute and convalescent sera. Most of the patients were presenting within a relatively late phase of the disease or with delayed manifestations of ARF where ASOT is already stabilized. Moreover, a rise in ASOT is less prominent in recurrent ARF compared to 1st attack, and acute and recurrent tonsillitis \[[@pntd.0008558.ref023]\]. It therefore loses its value as an index of the inflammatory activity of the disease \[[@pntd.0008558.ref024]\], although an absolute value of ASO titre can be of diagnostic importance \[[@pntd.0008558.ref025]\].

To confirm the diagnosis of RHD, each individual underwent ECG and colour Doppler echocardiography. For a definite diagnosis of RHD, detailed transthoracic two-dimensional and Doppler studies were performed in all cases by experienced echocardiographers and reviewed by consultant cardiologists for confirming the diagnosis. Echocardiographic diagnosis of RHD was performed according to the standard criteria set by the 2012 World Heart Federation \[[@pntd.0008558.ref008]\], using GE. RT 6800 and Siemens Acuson CV-70 ultrasound systems. Briefly, standard transthoracic echocardiography (GE, Vivid 8, Chicago, USA) was performed in which 2D, M-mode, colour and Doppler modalities were used with images taken from the parasternal long axis, parasternal short axis, apical four chamber, apical five chamber and subcostal views. The combined use of Doppler-based and morphology-based criteria (any amount of valvular regurgitation (regurgitant jet \>1 cm in length, regurgitant jet in at least two planes, mosaic colour jet with a peak velocity \>2.5 m/sec, and persistent jet throughout systole or diastole) noted in at least two planes associated with at least two of the following morphological signs: restricted leaflet mobility, abnormal subvalvular thickening, or focal or generalized valvular thickening) had a three to four times higher rate of detection of subclinical RHD compared with the exclusive use of Doppler-based criteria \[[@pntd.0008558.ref026]\]. The severity of valvular lesion was qualitatively graded from 0 to 4 (0: absent, 1; trivial, 2; mild, 3; moderate, 4; severe) \[[@pntd.0008558.ref014],[@pntd.0008558.ref027],[@pntd.0008558.ref028]\].

Detected cases were offered a free standard of care according to their health status \[[@pntd.0008558.ref029]\]. Antibiotic prophylaxis as well as echocardiography check-ups were offered at no expense to all patients, while those in need of heart surgery were referred to El-Mahalla cardiac centre (a tertiary care centre which provides tertiary care for RHD patients referred from El-Mahalla RHD centre as well as for congenital heart disease and coronary artery disease cases refereed from other primary health care centres).

Prevention of ARF and RHD {#sec010}
-------------------------

Antibiotic treatment of GABHS infections to prevent first attacks of ARF (primary prophylaxis) or prophylaxis for preventing its recurrent episodes (secondary prophylaxis) are given according to the regimens described in [S1 Table](#pntd.0008558.s001){ref-type="supplementary-material"} \[[@pntd.0008558.ref030]\].

Statistical analysis {#sec011}
--------------------

The collected data were reviewed for accuracy and integrity and fed into computer software. Data were analysed using a statistical software package (SPSS Statistics Base 21.0, IBM, Armonk, NY). Continuous variables were presented as the mean ± standard deviation (SD). Categorical variables were expressed as numbers with proportions, n (%). Variables relevant to laboratory data were dichotomized according to prefixed cut-offs, taking into consideration the normal reference values.

We compared the baseline sociodemographic, clinical, and laboratory characteristics of individuals with ARF/RHD or individuals with misdiagnoses with completely free subjects. Continuous variables were compared using an independent-samples *t*-test. Categorical variables were compared by chi-squared test or Fisher's exact test. The variables associated with ARF/RHD at the *p* \<0.05 significance level in univariate analyses and deemed potentially useful for clinical prediction, were selected for multivariable analysis. The selected variables were entered as covariates to develop a multivariable logistic regression equation by backward Wald stepwise elimination, with rheumatic condition/misdiagnosis being the outcome variable.

Results {#sec012}
=======

Burden of RHD from 1998 to 2018 {#sec013}
-------------------------------

Between 1998--2018, El-Mahalla cardiac centre conducted 2680 open-heart surgeries for valve replacement in complicated RHD cases referred from El-Mahalla RHD centre. This represented 46.1% of all cardiac operative procedures performed in El-Mahalla cardiac centre alone, and placed a total cost of approximately 358 million Egyptian pounds (EGP) ([Fig 2](#pntd.0008558.g002){ref-type="fig"}).

![Total number of RHD operative procedures and expenditures in the El-Mahalla tertiary care cardiac centre (1998--2018).\
**Footnote of Fig 2:** RHD; rheumatic Heart disease, CABG; Coronary artery bypass grafting, CHD; Congenital heart disease, EGP; Egyptian pound.](pntd.0008558.g002){#pntd.0008558.g002}

During the study period (2006--2018), and among a total of 17014 suspected rheumatic cases, an average of 1308 subjects were screened per year. We identified an average of 360 new cases with ARF/RHD per year \[average 32.3% (±10.7) of the screened subjects\]. The number of screened subjects rose steeply late in the decade. Meanwhile, the proportion of the identified rheumatic patients showed a continuous decline over time, whereas that of misdiagnoses lingered behind ([Fig 3](#pntd.0008558.g003){ref-type="fig"}). The number of cases diagnosed with Rh.A was consistently higher compared to the number of confirmed RHD cases (average 164 cases per year), although the latter showed an unusual peak in 2018 ([S1 Fig](#pntd.0008558.s006){ref-type="supplementary-material"}).

![Number of screened subjects versus the number of cases diagnosed with rheumatic fever or its sequelae per year, in El-Mahalla canter (2006--2018).](pntd.0008558.g003){#pntd.0008558.g003}

The highest disease incidence season was late in winter and early in spring (February to April, with 27.8% of cases), closely followed by summer and early autumn (July to September, with 25.0% of cases) ([S2 Fig](#pntd.0008558.s007){ref-type="supplementary-material"}).

Characteristics of the screened cohort {#sec014}
--------------------------------------

The overall mean age of the evaluated cohort was 13.5 ± 8.5 years (age range 2--69, median = 11). The majority were in the age group 5--15 years (64.6%), female (63.2%), rural residents (61.2%), single (52.5%), educated at the primary level (43.0%), and of low socioeconomic status (50.2%). Approximately 2.4% were smokers \[85.3% in age group \>25 years and 14.7% in age group (18 - \<25 years)\], whereas 27.5% experienced second-hand smoking \[86.3% in children \<18 years, 10.3% in youth (18 - \<25 years) and 3.4% in adults \> 25 years\]. Most of the screened individuals (87.3%) were referred to the centre by health care providers, although 23.7% reported having no access to health care services ([Table 1](#pntd.0008558.t001){ref-type="table"}).

10.1371/journal.pntd.0008558.t001

###### Sociodemographic characteristics of the screened cohort.

![](pntd.0008558.t001){#pntd.0008558.t001g}

                                      Total Participants (n = 17014)   Total        Univariate analysis   Multivariate analysis                                                                             
  ----------------------------------- -------------------------------- ------------ --------------------- ----------------------- ---------- ---------- -------------- ----------- ---------- ------------- -------------
  **Age (Years)**                                                                                                                                                                                           
      \<5                             654                              5.3          95                    2.0                     749        4.4                                                            **0.008**
      5 --\<15                        8289                             67.1         2706                  58.0                    10995      64.6                      1.03        0.72       1.48          0.867
      15 --\<30                       2705                             21.9         1398                  30.0                    4103       24.1       **\<0.001**    **1.87**    **1.11**   **3.16**      **0.019**
      30--50                          678                              5.5          411                   8.8                     1089       6.4                       1.93        0.93       4.02          0.079
      50+                             22                               0.2          56                    1.2                     78         0.5                       **5.62**    **1.80**   **17.6**      **0.003**
  **(Mean ± SD)**                     12.7 ± 7.9                       15.6 ± 9.8   13.5 ± 8.5            **\<0.001**                                                                                       
  **Smoking**                                                                                                                                                                                               
      Yes                             259                              2.1          149                   3.2                     408        2.4        **\<0.001**    1.29        .961       1.72          0.090
      Passive (second hand smoking)   3659                             29.6         1029                  22.1                    4688       27.5       0.08           **1.14**    **1.02**   **1.27**      **0.016**
  **Sex**                                                                                                                                                                                                    
      Male                            4795                             38.8         1464                  31.4                    6259       36.8       **\<0.001**                                          
      Female                          7553                             61.2         3202                  68.6                    10755      63.2       **1.20**       **1.10**    **1.32**   **\<0.001**   
  **Residence**                                                                                                                                         ** **                                                
      Rural                           7755                             62.8         2661                  57.0                    10416      61.2       **\<0.001**                                          
      Urban                           4593                             37.2         2005                  43.0                    6598       38.8       **1.16**       **1.06**    **1.27**   **0.001**     
  **Education**                                                                                                                                         ** **                                                
      Illiterate                      237                              1.9          167                   3.6                     404        2.4        **\<0.001**                                         0.053
      Read and Write                  297                              2.4          252                   5.4                     549        3.2        1.53           0.80        2.92       0.195         
      Kindergarten                    1874                             15.2         333                   7.1                     2207       13.0       **1.89**       **1.08**    **3.29**   **0.025**     
      Primary                         5485                             44.4         1835                  39.3                    7320       43.0       **1.32**       **1.05**    **1.66**   **0.017**     
      Preparatory                     1921                             15.6         821                   17.6                    2742       16.1       **1.46**       **1.10**    **1.94**   **0.009**     
      Secondary                       1921                             15.6         961                   20.6                    2882       16.9       1.24           0.78        1.98       0.354         
      University                      613                              5.0          297                   6.4                     910        5.3        1.02           0.56        1.87       0.950         
  **Father\'s occupation**                                                                                                                                                                                   
      Working                         11159                            94.9         3997                  92.1                    15156      94.3       **\<0.001**                                          
      Not working                     244                              2.1          118                   2.7                     362        2.3                                                            
      Retired                         354                              3.0          223                   5.1                     577        3.6                                                            
  **Mother\'s occupation**                                                                                                                              ** **                                                
      Working                         1835                             15.0         564                   12.3                    2399       14.1       ** \<0.001**                                         
      Not Working                     10391                            85.0         4025                  87.7                    14416      84.7       **1.26**       **1.14**    **1.39**   **.004**      
  **Parents**                                                                                                                                                                                                
      Alive                           11744                            95.2         4323                  92.5                    16067      94.4       **\<0.001**                                          
      Died                            597                              4.8          350                   7.5                     947        5.6                                                            
  **Marital status**                                                                                                                                    ** **                                                
      Single                          1565                             54.6         766                   48.7                    2331       52.5       **\<0.001**    **0.66**    **0.55**   **0.80**      **\<0.001**
      Married                         1267                             44.2         791                   50.3                    2058       46.4       0.91           0.73        1.14       0.404         
      Widowed                         11                               0.4          7                     0.4                     18         0.4        0.33           0.10        1.02       0.054         
      Divorced                        23                               0.8          9                     0.6                     32         0.7        0.93           0.38        2.25       0.869         
  **Income**                                                                                                                                                                                                 
      Not enough                      6125                             49.6         2411                  51.6                    8536       50.2       **0.022**      **1.57**    **1.43**   **1.72**      **\<0.001**
      Enough                          6216                             50.4         2262                  48.4                    8478       49.8                                                           
  **Family Size**                                                                                                                                       ** **                                                
      1--3                            743                              6.0          283                   6.1                     1026       6.0                                                             
      4--8                            11494                            93.1         4300                  92.2                    15794      92.8       **\<0.001**                                          
      \>8 (9--15)                     111                              0.9          83                    1.8                     194        1.1                                                             
  **(Mean ± SD)**                     12.7 ± 7.9                       15.6 ± 9.8   13.5 ± 8.5            **\<0.001**             **1.05**   **1.01**   **1.1**        **0.014**                            
  **Crowding Index**                                                                                                                                    ** **                                                
      1--2                            11960                            96.9         4391                  94.1                    16351      96.1                                                           0.009
      3--5                            342                              2.8          242                   5.2                     584        3.4        **\<0.001**    **1.55**    **1.13**   **2.13**      **0.007**
      \>5 (6--11)                     46                               0.4          33                    0.7                     79         0.5                       **3.02**    **1.35**   **6.78**      **0.007**
  **(Mean ± SD)**                     1.6 ± 0.62                       1.7 ± 0.8    13.5 ± 8.5            **\<0.001**             ** **      ** **      ** **          ** **                                
  **Ventilation**                                                                                                                                       ** **                                                
      Good                            9003                             72.9         2823                  60.5                    11826      69.5                                                           **\<0.001**
      Average                         3071                             24.9         1619                  34.7                    4690       27.6       **\<0.001**    **1.72**    **1.54**   **1.91**      **\<0.001**
      Bad                             274                              2.2          224                   4.8                     498        2.9                       **1.75**    **1.31**   **2.34**      **\<0.001**
  **Medical service**                                                                                                                                   ** **                                                
      None                            2443                             19.8         1591                  34.0                    4034       23.7       **\<0.001**    **1.85**    **1.17**   **2.93**      **0.009**
      Private health care services    6814                             55.2         2311                  49.5                    9125       53.6       1.18           0.74        1.90       0.482         
      Health Insurance                2259                             18.3         545                   11.7                    2804       16.5       0.86           0.54        1.38       0.542         
      PHC units                       535                              4.3          84                    1.8                     619        3.6        0.74           0.43        1.29       0.285         
      University Hospitals            8                                0.1          3                     0.1                     11         0.1        1.40           0.13        15.12      0.781         
      Public Hospitals                282                              2.3          139                   3.0                     421        2.5        ** **          ** **       ** **      **\<0.001**   
  **Referral method**                                                                                                                                                                                        
      Health care Physician           10274                            83.3         4584                  98.1                    14858      87.3       **\<0.001**    **6.98**    **2.56**   **19.07**     **\<0.001**
      Family                          638                              5.2          18                    0.4                     656        3.9        0.91           0.30        2.77       0.862         
      Advertisement                   928                              7.5          59                    1.3                     987        5.8        1.39           0.49        3.94       0.540         
      Friend                          3                                0.0          1                     0.0                     4          0.0        3.76           0.22        65.4       0.364         
      Neighbours                      426                              3.5          5                     0.1                     431        2.5        0.29           0.07        1.10       0.068         
      Others                          72                               0.6          6                     0.1                     78         0.5                                              **\<0.001**   

PHC = primary health care

Characteristics of rheumatic patients {#sec015}
-------------------------------------

Among the screened individuals attending El-Mahalla RHD centre, a total of 4666 (27.4%) subjects were rheumatic presenting with ARF or its sequelae \[carditis/RHD (10.8%), Rh.A (14.9%), Sydenham's chorea \[a total of 8 cases (0.05%); combined with carditis/RHD in 6 cases (75.0%)\], and both carditis/RHD and Rh.A (1.8%)\]. Importantly, the disease was ruled out in 37.7% of the enrolled subjects (misdiagnoses) who were referred to the centre as ARF/RHD cases. The predominant sociodemographic and clinical features of rheumatic patients are depicted in [Table 1](#pntd.0008558.t001){ref-type="table"}, [Table 2](#pntd.0008558.t002){ref-type="table"} and [Fig 4](#pntd.0008558.g004){ref-type="fig"}.

![Age distribution of acute rheumatic fever and rheumatic heart disease patients.](pntd.0008558.g004){#pntd.0008558.g004}

10.1371/journal.pntd.0008558.t002

###### Clinical presentation of the screened cohort.

![](pntd.0008558.t002){#pntd.0008558.t002g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Total Participants (n = 17014)   Total           Univariate analysis   Multivariate analysis                                                                    
  ------------------------------------------ -------------------------------- --------------- --------------------- ----------------------- ------- ------ ------------- ---------- ---------- ------------- -------------
  **Symptoms**                                                                                                                                                                                                

      Tonsillitis                            3101                             25.1            1564                  33.5                    4665    27.4   **\<0.001**   **1.31**   **1.20**   **1.42**      **\<0.001**

      Pharyngitis                            995                              8.1             427                   9.2                     1422    8.4    **0.024**     1.10       0.98       1.30          0.081

      Breathlessness/Dyspnea on effort       7278                             58.9            2043                  43.8                    9321    54.8   **0.004**     **0.78**   **0.71**   **0.86**      **\<0.001**

      Arthralgia                             932                              7.5             42                    0.9                     974     5.7    **\<0.001**   **0.21**   **0.15**   **0.29**      **\<0.001**

      Arthritis                              623                              5.0             1935                  41.5                    2558    15.0   **\<0.001**   **11.0**   **9.70**   **12.4**      **\<0.001**

      Fever                                  279                              2.3             182                   3.9                     461     2.7    **\<0.001**   1.05       0.83       1.31          0.696

      Others                                 125                              1.0             18                    0.4                     143     0.8    **\<0.001**   **0.22**   **0.12**   **0.42**      **\<0.001**

  **Recurrent attacks of tonsillitis**                                                                                                                                                                       

      Yes                                    5803                             47.0            2769                  59.3                    8572    50.4   **\<0.001**                                       **\<0.001**

          ≤ 6 attacks per year               5121                             41.5            2354                  50.4                    7475    43.9   **\<0.001**   **1.70**   **1.20**   **2.40**      **0.001**

          \> 6 attacks per year (up to 27)   682                              5.5             415                   8.9                     1097    6.4    **2.80**      **2.00**   **4.00**   **\<0.001**   

  **Tonsillectomy**                                                                                                                                                                                          

      Yes                                    3831                             31.0            1755                  37.6                    5586    32.8   **\<0.001**                                        

  **Hospitalization**                                                                                                                                                                                        

      Cardiac                                40                               0.3             114                   2.4                     154     0.9    **\<0.001**   **2.80**   **1.80**   **4.40**      **\<0.001**

      Others                                 805                              6.5             438                   9.4                     1243    7.3    **\<0.001**   1.10       0.90       1.20          0.410

  **Echocardiography**                                                                                                                                                                                       

      Normal                                 12348                            100.0           2535                  54.3                    14876   87.4                                                      

      MS                                     0                                0.0             25                    0.5                     25      0.1                                                       

      MR                                     0                                0.0             1740                  37.3                    1740    10.2                                                      

      AS                                     0                                0.0             6                     0.1                     6       0.0                                                       

      AR                                     0                                0.0             90                    1.9                     90      0.5                                                       

      TR                                     0                                0.0             233                   5.0                     233     1.4                                                       

      AR + MR                                0                                0.0             31                    0.7                     31      0.2                                                       

      MR + MS + AR                           0                                0.0             4                     0.1                     4       0.0                                                       

      MS + AR                                0                                0.0             3                     0.1                     3       0.0                                                       

      MR + TR                                0                                0.0             1                     0.0                     1       0.0                                                       

      MR + MS                                0                                0.0             4                     0.1                     4       0.0                                                       

      MR + AS + AR                           0                                0.0             1                     0.0                     1       0.0                                                       

  **Degree of valvular affection**                                                                                                                                                                            

      Trivial                                0                                0.0             241                   11.3                    241     1.4                                                       

      Mild                                   0                                0.0             1635                  76.5                    1635    9.6                                                       

      Moderate                               0                                0.0             220                   10.3                    220     1.3                                                       

      Sever                                  0                                0.0             42                    1.9                     41      0.2                                                       

  **Diagnosis**                                                                                                                                                                                               

      Normal                                 5930                             48.1            0                     0.0                     5930    34.8                                                      

      Others (misdiagnosis)                  6411                             51.9            0                     0.0                     6411    37.7                                                      

      Carditis/RHD                           0                                0.0             1830                  39.2                    1830    10.8                                                      

      Rheumatic arthritis                    0                                0.0             2533                  54.2                    2533    14.9                                                      

      Sydenham's chorea                      0                                0.0             2                     0.0003                  2       0.0                                                       

      RHD and Rheumatic arthritis            0                                0.0             302                   6.5                     302     1.8                                                       

      RHD and Sydenham's chorea              0                                0.0             6                     0.1                     6       0.0                                                       

  **Major criteria of RF**                                                                                                                                                                                    

      Carditis                               0                                0.0             2138                  45.8                    2138    12.6                                                      

      Arthritis                              0                                0.0             2835                  60.7                    2835    16.7                                                      

      Sydenham's Chorea                      0                                0.0             8                     0.2                     8       0.0                                                       

  **Minor criteria of RF**                                                                                                                                                                                    

      ASOT (Mean ± SD)                       424.2 ± 167.6                    438.0 ± 181.0   427.4 ± 170.4         0.460                                                                                    

      ESR 1st hr (Mean ± SD)                 20.7 ± 13.3                      26.4 ± 17.3     96.1 ± 22.3           **0.002**                                                                                

  **History of receiving BPG**                                                                                                                             **\<0.001**                                        

      Yes                                    6430                             52.1            3406                  72.9                    9836    57.8   **3.30**      **2.90**   **3.80**   **\<0.001**   

  **BPG regimen**                                                                                                                                          ** **                                              

      2 weeks                                5611                             87.3            2853                  83.8                    8464    86.1   \                                                  
                                                                                                                                                           **\<0.001**                                       

      3 weeks                                158                              2.5             96                    2.8                     254     2.6                                                      

      4 weeks                                661                              10.3            457                   13.4                    1118    11.4                                                     

          Adherent                           4039                             62.8            1820                  53.4                    5859    59.6   **\<0.001**   **0.75**   **0.67**   **0.84**      **\<0.001**

          Non-adherent                       2391                             37.2            1586                  46.6                    3977    40.4                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AR = Aortic regurgitation; AS = Aortic stenosis; ASOT = Antistreptolysin-O titre; BPG = Benzathine penicillin G; ESR = erythrocyte sedimentation rate; MR = mitral regurgitation; MS = mitral stenosis; RHD = rheumatic heart disease; TR = tricuspid regurgitation

Recurrent attacks of tonsillitis and tonsillectomy {#sec016}
--------------------------------------------------

Rheumatic patients were more likely to experience recurrent attacks of tonsillitis (59.3%; ranged in number between 1--27 attacks per year) and eventually underwent tonsillectomy (65.2%) ([Table 1](#pntd.0008558.t001){ref-type="table"}). A considerable number of the latter eventually developed ARF complications \[carditis/RHD (10.8%), Rh.A (19.2%), carditis/RHD and Sydenham's chorea (0.1%), and combined carditis/RHD and Rh.A (2.2%)\] ([S1 Table](#pntd.0008558.s001){ref-type="supplementary-material"}). In most tonsillectomy patients (93.9%), the frequency of tonsillitis was less than 6 attacks per year ([Fig 5](#pntd.0008558.g005){ref-type="fig"}).

![Tonsillectomy among cases with a history of recurrent attacks of tonsillitis attending the El-Mahalla RHD centre (2006--2018).](pntd.0008558.g005){#pntd.0008558.g005}

Use of BPG {#sec017}
----------

Almost 58.0% of the study cohort was receiving BPG injections as ARF secondary prophylaxis, mainly on biweekly basis (83.8%), although only 53.4% of them adhered to the regimen. The use of a 3-week or a 4-week BPG regimens and the lack of compliance with its use were remarkable features among rheumatic patients compared to their normal peers (*p*\< 0.05). Almost one-third of those who reported receiving BPG injections as ARF secondary prophylaxis eventually developed ARF complications (12.2% carditis/RHD, 20.0% Rh.A, 0.05% carditis/RHD and Sydenham's chorea, and 2.3% carditis/RHD and Rh.A) ([S2 Table](#pntd.0008558.s002){ref-type="supplementary-material"}). The use of BPG was more common among patients experiencing recurrent attacks of tonsillitis, although the non-adherence rate and rate of administration of BPG injections every 3^rd^ or 4^th^ week were significantly higher in these patients compared to those with no frequent tonsillitis ([S3 Table](#pntd.0008558.s003){ref-type="supplementary-material"}).

Echocardiography of rheumatic patients {#sec018}
--------------------------------------

In total, 12.6% of the screened subjects had clinical evidence of cardiac valvular damage due to ARF. Valvular involvement was predominately mitral (89.8%), mild (76.5%) and regurgitant (91.3%). The majority of RHD patients had mitral regurgitation (81.4%) and less frequently had mitral stenosis (11.3%), tricuspid regurgitation (10.9%), aortic stenosis (10.3%), or aortic regurgitation (1.9%). Triple and double valvular involvements did not exceed 1.5% ([Table 2](#pntd.0008558.t002){ref-type="table"}). The degree of valvular affection and the associated factors are detailed in [S4 Table](#pntd.0008558.s004){ref-type="supplementary-material"}.

Misdiagnosis of ARF and its sequelae {#sec019}
------------------------------------

We ruled out ARF/RHD in a significant number (37.7%) of a group of the participants who were previously misdiagnosed as rheumatic patients and were un-necessarily on BPG secondary prophylaxis regimens as recommended by their health care providers. Misdiagnosed cases tended to present with breathlessness/dyspnoea on effort (which significantly correlated with smoking history) (60.7%), tonsillitis (52.5%), arthralgia (7.9%) or other non-specific symptoms (0.9%) (*p* \<0.05) ([Table 3](#pntd.0008558.t003){ref-type="table"}).

10.1371/journal.pntd.0008558.t003

###### Factors associated with misdiagnosis of rheumatic fever and its sequelae.

![](pntd.0008558.t003){#pntd.0008558.t003g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Misdiagnosis    Univariate analysis   Multivariate analysis                                                                     
  ------------------------------------------ --------------- --------------------- ----------------------- ---------- -------------- ----------- ------------- ------------- -------------
  **Age (Years)**                            ** **                                                                                                                           

      \<5                                    132             2.1                   617                     5.8        **\<0.001**                                            **\<0.001**

      5 --\<15                               3752            58.5                  7243                    68.3       0.72           0.42        1.21          0.212         

      15 --\<30                              2013            **31.4**              2090                    19.7       **0.44**       **0.24**    **0.78**      **0.005**     

      30--50                                 505             **7.9**               584                     5.5        **0.38**       **0.20**    **0.72**      **0.003**     

      50+                                    22              0.2                   56                      1.2        **0.03**       **0.01**    **0.07**      **\<0.001**   

  **(Mean ± SD)**                            12.6 ± 8.6      14.9 ± 8.4            **\<0.001**                                                                               

  **Smoking**                                                                                                                                                                

      Yes                                    166             2.6                   229                     2.2        **0.032**      **0.57**    **0.40**      **0.81**      **0.002**

      passive                                1586            24.7                  2349                    22.2       **\<0.001**    0.95        0.82          1.10          0.485

  **Sex**                                                                                                                                                                     

      Male                                   2136            33.3                  4123                    38.9       **\<0.001**                                             

      Female                                 4275            66.7                  6480                    61.1                                                ** **         

  **Residence**                                                                                                       ** **                                                   

      Rural                                  4157            64.8                  6259                    59.0       **\<0.001**    **1.20**    **1.10**      **1.40**      **0.001**

      Urban                                  2254            35.2                  4344                    41.0                                                              

  **Education**                                                                                                       ** **                                                   

      Illiterate                             162             2.5                   242                     2.3        **\<0.001**\   0.98        0.64          1.49          0.907

      Read and Write                         198             3.1                   351                     3.3        0.83           0.57        1.21          0.334         

      Kindergarten                           480             7.5                   1727                    16.3       **0.52**       **0.37**    **0.71**      **\<0.001**   

      Primary                                2485            38.8                  4835                    45.6       **0.68**       **0.48**    **0.95**      **0.026**     

      Preparatory                            1180            18.4                  1562                    14.7       **0.72**       **0.53**    **0.99**      **0.044**     

      Secondary                              1451            22.6                  1431                    13.5       0.87           0.69        1.09          0.226         

      University                             613             5.0                   297                     6.4                                                 **\<0.001**   

  **Father\'s occupation**                                                                                                                                                    

      Working                                128             2.1                   234                     2.3                                                                

      Not working                            5664            94.2                  9492                    94.1       **0.002**                                               

      Retired                                220             3.7                   357                     3.5                                                                

  **Mother\'s occupation**                                                                                            ** **                                                   

      Working                                5447            86.0                  8969                    85.6                                                               

      Not Working                            888             14.0                  1511                    14.4       0.763                                                  ** **

  **Parents**                                                                                                                                                                 

      Alive                                  5936            92.6                  9960                    93.9       **\<0.001**                                             

      Died                                   475             7.4                   643                     6.1                                                               

  **Marital status**                                                                                                  ** **                                                   

      Single                                 1113            52.6                  1218                    52.4       **\<0.001**    1.04        0.80          1.35          0.774

      Married                                977             46.2                  1081                    46.5       **1.40**       **1.13**    **1.74**      **0.002**     

      Widowed                                10              0.5                   8                       0.3        2.93           0.80        10.71         0.104         

      Divorced                               16              0.8                   16                      0.7        0.98           0.33        2.90          0.971         

  **Income**                                                                                                                                                                  

      Not enough                             6125            49.6                  2411                    51.6       **0.022**                                               

      Enough                                 6216            50.4                  2262                    48.4       1.60           1.40        1.80          **\<0.001**   

  **Family Size**                                                                                                     ** **                                                   

      1--3                                   456             7.1                   570                     5.4                                                               0.001

      4--8                                   5880            91.7                  9912                    93.5       **\<0.001**    **0.71**    **0.56**      **0.90**      **0.004**

      \>8 (9--15)                            75              1.2                   121                     1.1                       **0.44**    **0.28**      **0.72**      **0.001**

  **(Mean ± SD)**                            5.03 ± 1.2      5.02 ± 1.18           0.511                   0.92       0.88           0.97        0.001                       

  **Crowding Index**                                                                                                  ** **          ** **       ** **         ** **          

      1--2                                   6175            96.3                  10176                   96.0       0.474                                                   

      3--5                                   206             3.2                   378                     3.6                                                 ** **         

      \>5 (6--11)                            30              0.5                   49                      0.5                                                 ** **         

  **(Mean ± SD)**                            1.58 ± 0.66     1.6 ± 0.7             0.062                   **1.20**   **1.09**       **1.32**    **\<0.001**                 

  **Ventilation**                                                                                                     ** **                                                   

      Good                                   4588            71.6                  7238                    68.3                      1.885       1.344         2.643         **\<0.001**

      Average                                1654            25.8                  3036                    28.6       **\<0.001**    1.19        0.86          1.65          0.301

      Bad                                    169             2.6                   329                     3.1                       ** **       ** **         ** **         **\<0.001**

  **Medical service**                                                                                                 ** **                                                   

      None                                   100             1.6                   3934                    37.1       **\<0.001**    **0.05**    **0.03**      **0.07**      **\<0.001**

      Private health care services           5736            89.5                  3389                    32.0       **1.42**       **1.03**    **1.95**      **0.031**     

      Health Insurance                       392             6.1                   2412                    22.7       1.20           .84         1.72          0.315         

      PHC units                              55              0.9                   564                     5.3        1.17           .65         2.10          0.595         

      Public Hospitals                       128             2                     304                     2.9                                                 **\<0.001**   

  **Referral method**                                                                                                                                                         

      Health care Physician                  6369            99.3                  8489                    80.1       **\<0.001**    **0.09**    **0.02**      **0.50**      **0.006**

      Family                                 12              0.2                   644                     6.1        0.92           0.06        14.2          0.954         

      Advertisement                          13              0.2                   974                     9.2        0.17           0.02        1.43          0.093         

      Friend                                 1               0.0                   3                       0.0        0.16           0.01        4.51          0.284         

      Neighbours                             4               0.1                   427                     4.0        **0.02**       **0.002**   **0.19**      **0.001**     

      Others                                 12              0.2                   66                      0.6                                                 **0.004**     

  Symptoms                                                                                                            * *                                                     

      Tonsillitis                            3367            52.5                  5510                    52.0       0.484                                                  ** **

      Pharyngitis                            479             7.5                   943                     8.9        **0.001**      **0.75**    **0.62**      **0.89**      **0.001**

      Breathlessness/Dyspnea on effort       3890            60.7                  5431                    51.2       **\<0.001**    **1.21**    **1.07**      **1.37**      **0.004**

      Arthralgia                             454             7.1                   520                     4.9        **\<0.001**    **5.51**    **3.50**      **8.68**      **\<0.001**

      Arthritis                              427             6.7                   2131                    20.1       **\<0.001**    **0.08**    **0.07**      **0.10**      **\<0.001**

      Others                                 59              0.9                   84                      0.8        0.376          **8.96**    **3.56**      **22.5**      **\<0.001**

  Recurrent attacks of tonsillitis                                                                                                                                            

  No                                                                                                                                 2.40        1.94          2.96          **\<0.001**

      Yes                                    3261            50.9                  5311                    50.1       0.327                                                   

          ≤ 6 attacks per year               2928            89.8                  4547                    85.6       **\<0.001**    1.88        1.54          2.29          **\<0.001**

          \> 6 attacks per year (up to 27)   333             10.2                  764                     14.4       **0.42**       **0.34**    **0.52**      **\<0.001**   

  **Major criteria of Rheumatic fever**                                                                                                                                      

  Carditis                                   0               0.0                   2138                    20.2       **\<0.001**                                            

  Arthritis                                  0               0.0                   2835                    26.7                                                              

  Sydenham's Chorea                          0               0.0                   8                       0.1                                                               

  **Minor criteria of Rheumatic fever**                                                                                                                                      

  ASOT (Mean ± SD)                           415.4 ± 165.8   434.8 ± 173.6         0.220                                                                                     

  ESR 1st hr (Mean ± SD)                     21.3 ± 13.5     22.8 ± 15.7           0.320                                                                                     

  **Tonsillectomy**                                                                                                                                                           

      Yes                                    2256            35.2                  3330                    31.4       **\<0.001**                                             

  **Hospitalization**                                                                                                                                                         

      Cardiac                                29              0.5                   125                     1.2        **\<0.001**    **0.28**    **0.17**      **0.47**      **\<0.001**

      Others                                 414             6.5                   829                     7.8        0.90           0.74        1.11          0.337         

  **History of taking BPG**                                                                                           ND                                                      

      Yes                                    6411            100.0                 3425                    32.3                                                              

  **BPG regimen**                                                                                                                                                             

      2 weeks                                5595            87.3                  2869                    83.8       **\<0.001**                                             

      3 weeks                                158             2.5                   96                      2.8                                                               

      4 weeks                                658             10.3                  460                     13.4                                                              

  **BPG Frequency**                                                                                                                                                           

      Adherent                               4023            **62.8**              1836                    53.6       **\<0.001 **   **1.45**    **1.28**      **1.63**      **\<0.001**

      Non-adherent                           2388            37.2                  1589                    46.4                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASOT = Antistreptolysin-O titre; BPG = Benzathine penicillin G; ESR = erythrocyte sedimentation rate; PHC = primary health care

Rheumatic fever among family members of RHD patients {#sec020}
----------------------------------------------------

Screening of family members of RHD patients who had valve replacement cardiac surgery, resulted in the detection of 20.7% rheumatic cases \[56.0% with RHD and 52.2% with Rh.A\]. These represented 3.4% of the total cases diagnosed with ARF and its complications ([S5 Table](#pntd.0008558.s005){ref-type="supplementary-material"}).

Multivariate analysis: ARF/RHD risk model {#sec021}
-----------------------------------------

In multivariate stepwise conditional logistic regression analyses, there was a trend towards acquiring ARF or developing RHD in association with age group 15 --\<30 years, female sex, urban residence, passive smoking, being in kindergarten, primary or preparatory school, having an unemployed mother, having a low income, having a large family size, a crowding index from 3 to 5 or \>5, living in average and poorly ventilated households; having no access to health care services, and being referred by a health care physician ([Table 1](#pntd.0008558.t001){ref-type="table"}). Rheumatic patients notably presented with repeated attacks of tonsillitis \[OR  =  1.31, 95% CI  =  1.2--1.42\] and arthritis \[OR  =  11.0, 95% CI  =  9.7--12.4\], and experienced more frequent hospitalization due to cardiac causes. Adherence to BPG prophylaxis apparently reduced ARF/RHD rates \[OR  =  0.75, 95% CI  =  0.67--0.84\] ([Table 2](#pntd.0008558.t002){ref-type="table"}).

On the other hand, misdiagnosed cases showed different sociodemographic features. Particularly, rural residence, being married, having enough income, having a small family size, having a high crowding index, living in a well-ventilated house, and utilizing private health care services. They initially presented with dyspnoea \[OR  =  1.21, 95% CI  =  1.07--1.37\], arthralgia \[OR  =  5.5, 95% CI  =  3.5--8.68\], or non-specific symptoms \[OR  =  8.9, 95% CI  =  3.6--22.5\], but never experienced recurrent attacks of tonsillitis \[OR  =  2.4, 95% CI  =  1.9--2.96\] and tended to have fewer than 6 attacks per year \[OR  =  1.9, 95% CI  =  1.5--2.3\]. Moreover, they never been hospitalized due to cardiac causes \[OR  =  0.28, 95% CI  =  0.17--0.47\], and were adherent to PBG use \[OR  =  1.45, 95% CI  =  1.28--1.63\] ([Table 3](#pntd.0008558.t003){ref-type="table"}).

Likewise, family members of RHD patients had a higher mean family size \[OR = 1.3, 95% CI =  1.07--1.57\], a higher crowding index \[OR = 8.6, 95% CI = 1.01--72.9\], no access to health care services \[OR = 3.3, 95% CI = 1.2--9.5\], and presented with pharyngitis \[OR = 2.04, 95% CI =  1.05--4.0\] or arthritis \[OR = 11.4, 95% CI =  6.6--19.8\] ([S5 Table](#pntd.0008558.s005){ref-type="supplementary-material"}).

Discussion {#sec022}
==========

The present data paint the unabated picture of rheumatic fever in Egypt and the heavy economic burden placed by RHD on the healthcare system. However, with the expansion of the national rheumatic heart disease prevention and control program screening capacity, the proportion of the identified rheumatic patients consistently declined over time. Furthermore, more ARF/RHD misdiagnoses were spotted and correctly diagnosed. This reflects the effectiveness of the program in achieving its objectives, particularly after gaining more national attention and governance from the Egyptian MOHP starting from the year 2014 onwards.

Characteristics of the screened cohort {#sec023}
--------------------------------------

The incidence of ARF is highest in children aged 5--15 years \[[@pntd.0008558.ref003]\]. This was consistent with findings from our study cohort, although we reported cases of ARF in patients as young as 2--4 years old. Children in the 5- to 15-year-old age group still have the highest risk for ARF in Egypt because at these ages, children are in schools that are badly ventilated and overcrowded; conditions that favour the spread of GABHS infections \[[@pntd.0008558.ref031]\]. This particular age-group vulnerability was suggested to be attributed to delayed antibody response and maturation processes in the immune system \[[@pntd.0008558.ref032]\]. We identified ARF in people older than 30 years. Although we could not correctly delineate whether these were initial or recurrent episodes, literature would suggest these cases are almost entirely recurrences \[[@pntd.0008558.ref001],[@pntd.0008558.ref004]\]. RHD is caused by accumulated heart valve damage from recurrent ARF episodes. However, the peak of its prevalence was observed among children in the age group 5--15 years, although RHD usually occurs in adulthood between the ages of 25 years and 45 years \[[@pntd.0008558.ref033]\]. This suggests that children frequently do not have their initial bout of ARF come to medical attention. In this context, children may be misdiagnosed with initial ARF when they are, in fact, experiencing a recurrence of ARF. The intensification of awareness-raising activities in recent years may help to reduce the extent of this problem in the future.

In most populations, ARF is equally common in males and females, although an increased risk of RHD in females has been found in almost all populations \[[@pntd.0008558.ref003],[@pntd.0008558.ref004],[@pntd.0008558.ref031],[@pntd.0008558.ref033],[@pntd.0008558.ref034]\], particularly in adolescents and adults rather than in children \[[@pntd.0008558.ref026],[@pntd.0008558.ref033]\]. Conversely, male sex predominance of valvular disease in ARF was previously reported in Nepali children \[[@pntd.0008558.ref035]\]. However, in the present cohort, all rheumatic presentations were more common in females, with a relative risk of 1.2 compared with males. For instance, the reason for this sex difference is not clear but could be attributed to intrinsic factors such as greater autoimmune susceptibility in females (influence of oestrogen on B cell response, T lymphocyte proliferation, profibrotic Th2 response and level of inflammatory cytokines) \[[@pntd.0008558.ref036],[@pntd.0008558.ref037]\], or extrinsic factors such as greater exposure to repeated GABHS infections in women than in men. It is likely that women are housebound, spending longer times engaged in indoor activities and exposes more to overcrowding under poor housing conditions. Moreover, in low social classes, health care seeking for women is constrained by sociocultural norms, and thus they get inequitable access to health care \[[@pntd.0008558.ref038]\]. The delay in the diagnosis of mild to moderate episodes of ARF among women may ultimately lead to a large population of female patients with RHD \[[@pntd.0008558.ref004]\]. Likewise, RHD is increasingly recognized during antenatal care and was reported as a leading cause of indirect obstetric death \[[@pntd.0008558.ref039]\].

Tackling the socioeconomic and environmental determinants of ARF is crucial in elucidating the disease epidemiology \[[@pntd.0008558.ref003],[@pntd.0008558.ref011]\]. Most social determinants of health are overlapping and their association with poverty and economic disadvantages are well documented \[[@pntd.0008558.ref026]\]. Household overcrowding is the most important factor underlying the high ARF incidence \[[@pntd.0008558.ref040],[@pntd.0008558.ref041]\]. With a higher family size in the evaluated participants, there was a notable increase in the rate of ARF and its sequelae, which may reflect the effect of household crowding and deprivation \[[@pntd.0008558.ref004],[@pntd.0008558.ref040],[@pntd.0008558.ref042]\]. This was consistent in previous reports from around the world \[[@pntd.0008558.ref003],[@pntd.0008558.ref004],[@pntd.0008558.ref009],[@pntd.0008558.ref010],[@pntd.0008558.ref011],[@pntd.0008558.ref031],[@pntd.0008558.ref033],[@pntd.0008558.ref034],[@pntd.0008558.ref041],[@pntd.0008558.ref042]\]. Likewise, a higher crowding index and poor ventilation obviously affected the occurrence of ARF and its complications in this cohort. In fact, ventilation is a key pillar of infection control in buildings thanks to the germicidal effect of direct sunlight \[[@pntd.0008558.ref043],[@pntd.0008558.ref044],[@pntd.0008558.ref045]\], and poor living conditions and deteriorated indoor environment could potentiate the transmission of bacterial pathogens such as GABHS. This was consistently documented in many studies \[[@pntd.0008558.ref003],[@pntd.0008558.ref004],[@pntd.0008558.ref031],[@pntd.0008558.ref033],[@pntd.0008558.ref034],[@pntd.0008558.ref041],[@pntd.0008558.ref046]\] except for a single report from India that found no clear difference in RHD occurrence between children living in homes with a higher crowding index and those living in less crowded households \[[@pntd.0008558.ref047]\].

ARF and RHD were found to be more common in patients from rural locations \[[@pntd.0008558.ref003],[@pntd.0008558.ref004]\], although in some studies, the risk was highest in impoverished urban regions, with overcrowding and poor housing conditions \[[@pntd.0008558.ref048],[@pntd.0008558.ref049]\]. Many Egyptian villages, including El-Mahalla, have experienced rapid urbanization, which has brought a population shift from rural to urban locations, leading to congested socioeconomically depressed localities. This clarifies why urban residence in the present cohort correlated with ARF and RHD. Furthermore, one-third of rheumatic patients had no access to health care services. In fact, the distance to a health centre can delay access to prophylactic medication and is an obstacle to adherence to regular BPG injections, a critical component of ARF secondary prevention \[[@pntd.0008558.ref041]\].

Low income was a noteworthy feature of rheumatic patients in the present study. ARF and RHD are diseases of poverty and can emerge in settings of social disruption \[[@pntd.0008558.ref050],[@pntd.0008558.ref051],[@pntd.0008558.ref052],[@pntd.0008558.ref053],[@pntd.0008558.ref054]\]. Children of unemployed mothers were found to be at greater risk of both ARF and RHD. In studies conducted in Fiji \[[@pntd.0008558.ref054]\] and Uganda \[[@pntd.0008558.ref041]\], maternal unemployment was a robust independent predictor of RHD. For instance, unemployment was a confounder of low literacy among mothers of rheumatic children. This link can be viewed as the effect of quality of care by educated mothers, awareness of simple ways to fight the disease, and appropriate use of health services \[[@pntd.0008558.ref004]\]. Moreover, unemployment has economic implications. The program in El-Mahala implements daily health education sessions targeting mothers and caregivers of children attending the centre for screening or follow-up of their condition. The key messages are the association between throat infections and ARF, and the importance of completing the antibiotic course to prevent the disease and its consequent complications.

In the present study, exposure to second-hand smoking was more encountered by the rheumatic patients than normal individuals. Plausibly, environmental tobacco smoke is an established risk factor for respiratory infections and may initiate ARF in susceptible individuals \[[@pntd.0008558.ref055]\] by altering oropharyngeal flora and increasing bacterial pathogens, including GABHS \[[@pntd.0008558.ref056]\]. In New Zealand, 71% of ARF patients lived in homes with at least one smoker \[[@pntd.0008558.ref057]\].

Clinical presentation and cardiac sequelae {#sec024}
------------------------------------------

The World Heart Federation Rheumatic Heart Disease Program reported that arthritis is the most common symptom in up to 75% of first episodes of ARF \[[@pntd.0008558.ref008]\]. This agrees with the presentations in our cohort. Mitral stenosis is common at the time of initial presentation in the developing world \[[@pntd.0008558.ref058]\] because many patients seek medical attention too late \[[@pntd.0008558.ref059]\]. However, the RHD control program in El-Mahalla succeeded in the early detection of cases of RHD before severe valvular involvement has occurred. Consistent with other local \[[@pntd.0008558.ref031],[@pntd.0008558.ref034]\] and worldwide \[[@pntd.0008558.ref026],[@pntd.0008558.ref035],[@pntd.0008558.ref060],[@pntd.0008558.ref061]\] studies, the majority of the RHD cases had mild mitral regurgitation. Trivial valvular effects were recorded for 241 (11.3%) patients who were counselled regarding the appropriate duration of secondary prophylaxis and advised to attend regular follow-up visits to prevent progressive damage to their valves.

Sydenham's chorea occurs in up to 30% of those who have ARF and is strongly associated with carditis \[[@pntd.0008558.ref003]\]. However, in our study cohort, it was an ARF presentation in less than 0.05% of cases, but was combined with carditis in 75% of the cases. This may reflect a noteworthy change in the clinical pattern of ARF.

Recurrent attacks of tonsillitis and tonsillectomy {#sec025}
--------------------------------------------------

Recurrent attacks of tonsillitis/pharyngitis were common among rheumatic patients compared to normal individuals. Similarly, Bassili et al. found that a history of tonsillitis was reported by one-third of the studied children \[[@pntd.0008558.ref062]\]. This is plausible since tonsillitis is a source of GABHS, which is implicated in the pathogenesis of ARF \[[@pntd.0008558.ref063],[@pntd.0008558.ref064]\]. Although most of the children experiencing repeated attacks of tonsillitis were advised to undergo tonsillectomy before the study, an appreciable number eventually developed ARF in its different presentations. In the Egyptian community, families make the decision to undergo tonsillectomy as a measure to prevent frequent respiratory infections or repeated attacks of tonsillitis and the attendant complications, although ARF and its sequelae may have been already established. Importantly and from the authors' experience, people who have their children tonsillectomized do not seek treatment for subsequent attacks of pharyngitis because they believe that tonsillectomy will interrupt the infection and protect against ARF and RHD. This reflects a low level of community awareness of the disease and inadequate expertise from the part of health care providers. There is strong evidence that tonsillectomy does not alter the susceptibility to infection with GABHS or its sequelae \[[@pntd.0008558.ref065],[@pntd.0008558.ref066],[@pntd.0008558.ref067],[@pntd.0008558.ref068],[@pntd.0008558.ref069]\]. Once that infection has been established, the presence or absence of the tonsils does not alter the clinical course of the disease. Moreover, it appears that streptococcal infections are less readily recognized in tonsillectomized patients and, therefore, are more likely to escape treatment appropriate for the prevention of ARF \[[@pntd.0008558.ref067],[@pntd.0008558.ref069]\].

Use of BPG {#sec026}
----------

We were not able to obtain accurate data about the primary prophylaxis of ARF as initially received by the participants for treating GABHS related diseases. As a matter of fact, the local practice of antibiotic treatment for children with pharyngitis and fever relies on self-medication with oral antibiotics dispensed from community pharmacies without prior consultations, appropriate prescriptions or indications \[[@pntd.0008558.ref070],[@pntd.0008558.ref071],[@pntd.0008558.ref072],[@pntd.0008558.ref073]\]. Moreover, some practitioners rely on a constellation of clinical features for presumptive treatment of streptococcal pharyngitis since bacterial culture and rapid diagnostic tests are not feasible \[[@pntd.0008558.ref074]\].

As secondary prophylaxis for ARF, the majority of the studied children reported receiving BPG injections mainly as a biweekly regimen, although half of them were not compliant with the regimen largely due to pain associated with the injection or a shortage of medicine supply in health care units. A 28-day BPG prophylaxis for at least 10 years was found to be safe and effective for patients with no or mild cardiac disease \[[@pntd.0008558.ref005],[@pntd.0008558.ref006]\]. Nevertheless, in agreement with the findings of Lue and co-workers \[[@pntd.0008558.ref075]\], patients receiving BPG every third/fourth week or the lack of compliance were strongly associated with the development of ARF or its recurrence. A Cochrane meta-analysis confirmed that injections every two or three weeks were more effective than 4-weekly regimens, although the evidence was based on poor quality trials \[[@pntd.0008558.ref076]\]. Studies on the serum penicillin levels in Egyptian children have shown a drop in the serum penicillin concentration to below the therapeutic level during the third week following the injection \[[@pntd.0008558.ref062],[@pntd.0008558.ref077]\]. Moreover, the difference in the pharmacokinetics of locally manufactured BPG compared to brand penicillin was found to contribute to the high recurrence rate of ARF reported in Egypt \[[@pntd.0008558.ref077],[@pntd.0008558.ref078]\]. Consequently, the national guidelines endorse the use of biweekly regimens for Egyptian patients until work on strengthening the BPG quality is successfully accomplished.

In the present report, the use of BPG as secondary prophylaxis for ARF did not reduce the risk of developing ARF related sequelae. Indeed, the treatment of existing GABHS infections may decrease the overall damage from that episode, but it will not eliminate or stop the progression of damage from the initial infection \[[@pntd.0008558.ref079]\]. Furthermore, one-third of ARF episodes results from non-symptomatic GABHS infections that go unnoticed and untreated \[[@pntd.0008558.ref029]\]. In community settings, the evidence to support injectable or oral penicillin treatment of GABHS pharyngitis to prevent the first presentation of ARF or decrease its frequency is still controversial \[[@pntd.0008558.ref003]\]. Prompt treatment of GABHS pharyngitis was postulated to remove the pathogen before an effective and prolonged immune response is elicited, leaving the host more susceptible to recurrent infections \[[@pntd.0008558.ref080],[@pntd.0008558.ref081]\]. However, this theory has been challenged in other studies \[[@pntd.0008558.ref082],[@pntd.0008558.ref083]\].

The efficacy of BPG as a secondary prophylaxis for ARF is limited by low patient adherence. A systematic, generalizable tool was developed by Balbaa and co-workers to outline and ultimately address these barriers. Adherence deterrents were the clinic wait time and the lack of knowledge of the nature of the disease or the consequences of missing prophylaxis doses \[[@pntd.0008558.ref084]\]. The delivery of secondary antibiotic prophylaxis should be performed by a dedicated health care team. Physician attention and informed discussions regarding treatment efficacy and life events empower people to take responsibility for their own wellbeing and contribute to better patient adherence \[[@pntd.0008558.ref079]\]. Maintaining adherence to BPG secondary prophylaxis might be prevented by physicians seeking to limit penicillin use in order to alleviate the development of antibiotic resistance. This highlights the importance of primary prevention through socioeconomic development, access to medical care, and reducing the prevalence of streptococcus in the environment. Another potential path to the primary prevention of ARF and to obviate the inherent BPG disadvantages is the development of a GABHS vaccine which is currently underway \[[@pntd.0008558.ref085],[@pntd.0008558.ref086]\].

Misdiagnosis of ARF and its sequelae {#sec027}
------------------------------------

The diagnosis of ARF remains challenging due to the changing pattern of the disease with a variety of clinical manifestations. In the present study, more than one-third of the evaluated participants that were previously diagnosed with ARF/RHD were found to be misdiagnosed and were regularly receiving unnecessary BPG. This undoubtedly increases the potential for adverse antibiotic reactions and creates excessive parental anxiety. The majority of the screened subjects, including the misdiagnosed patients, were referred to the El-Mahala RHD centre by health care practitioners in the private sector, who lack training and access to echocardiography.

As a matter of fact, ARF is a neglected disease, and physicians are only vaguely aware of the disorder. In this regard, capacity building, empowerment, and far greater awareness-raising endeavours amongst Egyptian health professionals are needed. Meanwhile, there is no biological marker for ARF, and its diagnosis is based on a constellation of clinical (Jones criteria) \[[@pntd.0008558.ref015]\] and laboratory evidence of previous streptococcal infections. However, the established criteria needed to make a diagnosis might not arise concurrently, and the initial illness may be mild and short-lived. This may result in underdiagnosis or overdiagnosis \[[@pntd.0008558.ref087]\]. The diagnosis will be missed if appropriate investigations are not carried out during the acute illness. On the other hand, too much reliance on elevated ASOT as a biomarker for GABHS throat infections preceding ARF or elevated acute phase reactants can result in unnecessary treatment. Likewise, the isolation of GABHS from a patient with tonsillitis/pharyngitis does not demonstrate a causal relationship. Not all individuals experiencing an untreated GABHS infection develop ARF. Moreover, not all strains of GABHS trigger an acute attack even in a highly susceptible host \[[@pntd.0008558.ref088]\].

Misdiagnosed patients were receiving un-necessary BPG on a regular basis, and during the interview, they named it "Hoknet Al-Tarseeb" in colloquial Arabic \[where; Hoknet = injection, Al = the, and Tarseeb = sedimentation or precipitation\], referring by that to an injection that is given when the ESR is high. This means that the diagnosis was incorrectly made by untrained practitioners on the basis of the elevated ESR when the patient initially presented with symptoms suggestive of ARF, without confirming or referring the suspected case to a specialized RHD clinic. An elevated ESR should alert a physician that ARF is likely when articular symptoms are observed, even in the absence of clinical carditis and before the echocardiologic findings can be reviewed \[[@pntd.0008558.ref089]\]. The possibility of misclassification in established RHD has increased in recent years, due to poor clinicians' auscultatory skills \[[@pntd.0008558.ref006]\]. Common sources of error in the diagnosis of ARF in children can include interpreting innocent murmur as the murmur associated with RHD; arthralgia as arthritis; abnormal movements as chorea; low-grade, persistent fever as ARF; clinical evidence of sore throat as GABHS infection (a variety of bacterial and viral agents can be implicated); and elevated ASOT as evidence of ARF \[[@pntd.0008558.ref090]\]. Furthermore, in many high-risk tropical areas, acute onset arthritis and fever are commonly caused by arboviral infections that should be considered and evaluated by testing whenever possible \[[@pntd.0008558.ref091]\].

Obviously, the results revealed that misdiagnosed cases had different sociodemographic and clinical features compared to rheumatic cases. They were more likely to present with breathlessness/dyspnoea or arthralgia rather than arthritis. Probably, breathlessness was a result of anaemia or an adverse effect of smoking in a number of these patients. Physicians must adhere to the revised Jones criteria \[[@pntd.0008558.ref015]\] for the diagnosis of ARF because atypical joint involvement and silent carditis can occur particularly in endemic areas, which can lead to misdiagnosis or delayed diagnosis and eventually ends in valvular damage \[[@pntd.0008558.ref015],[@pntd.0008558.ref022],[@pntd.0008558.ref089],[@pntd.0008558.ref092]\]. Echocardiography is the gold standard in swiftly confirming or ruling out acute carditis or established valvular involvement in questionable cases \[[@pntd.0008558.ref093]\].

To reduce misdiagnoses in the future, our study supports that the work-up for ARF should include an echocardiogram and that its finding should be scored as a major criterion for the diagnosis of RHD. Physician education and clear revised guidelines are necessary to ensure adequate management of individuals with ARF.

Risk ARF and RHD in family members {#sec028}
----------------------------------

RHD is known to cluster in families although it cannot be transmitted directly from parents to their children. The molecular basis of ARF and the subsequent RHD remains poorly understood \[[@pntd.0008558.ref003],[@pntd.0008558.ref007]\]. As inferred from the present study, children of RHD patients are prone to acquire ARF and develop RHD compared to their peers in the community borne to parents not suffering from the disease. Similar findings were reported among school children in sub-Saharan Africa \[[@pntd.0008558.ref094]\]. This suggests a familial tendency or genetic predisposition to the disease that can be aggravated by social factors and environmental conditions shared by inhabitants of the same household and favouring the occurrence of ARF. The genetic susceptibility to ARF and RHD was well documented in certain countries, including Australia, India, Egypt, and Turkey \[[@pntd.0008558.ref003],[@pntd.0008558.ref004],[@pntd.0008558.ref095],[@pntd.0008558.ref096],[@pntd.0008558.ref097]\], but no work to show this has been done in African countries. Susceptibility to ARF was found to be genetically determined, supported by phenotypic concordance among dizygotic twins \[[@pntd.0008558.ref095]\] and linked to polymorphisms in several genes coding for immune-related proteins \[[@pntd.0008558.ref003],[@pntd.0008558.ref096],[@pntd.0008558.ref098],[@pntd.0008558.ref099],[@pntd.0008558.ref100]\]. Apparently, susceptibility to ARF and RHD are polygenic and potentially inked to HLA loci, B-cell alloantigens, and immune-modulatory genes. Specific HLA class II haplotype conferred strong protection against ARF \[[@pntd.0008558.ref096],[@pntd.0008558.ref098],[@pntd.0008558.ref099],[@pntd.0008558.ref100]\], whereas others increased the risk of rheumatic disease in Egyptian \[[@pntd.0008558.ref063],[@pntd.0008558.ref101]\], Latvian \[[@pntd.0008558.ref098],[@pntd.0008558.ref099]\] and Taiwanese children \[[@pntd.0008558.ref102]\]. Moreover, a B cell alloantigen (D8/17) was detected in rheumatic patients and their family members \[[@pntd.0008558.ref003]\]. Whole-genome studies of susceptibility to ARF and RHD are anticipated in a number of high-incidence settings, which may provide further insights in the coming years \[[@pntd.0008558.ref096],[@pntd.0008558.ref097]\].

Admittedly, genetics differ among different populations and are not strong enough to indicate a need for screening and primary prophylaxis. But having a family history of ARF or RHD critically changes the pre-test probability of a diagnosis of rheumatic fever in someone presenting with suggestive symptoms, as was recently introduced in the revised Jones criteria algorithm for high-risk individuals \[[@pntd.0008558.ref015]\].

Study limitations {#sec029}
-----------------

Limitations in the current report entail the use of health program based consecutive sampling instead of community-based sampling which would provide more precise prevalence data. Thus, the present data appear as a surrogate to describe the magnitude of ARF/RHD in the referral communities. Besides, our investigation did not focus on finding new factors that might pose an increased risk, rather looked for the recognized risk factors and how these operate in the Egyptian population. Data about housing conditions were based on interviewing the participants and have not been ascertained through household visits due to time and resource constraints.

Conclusions {#sec030}
===========

Collectively, ARF continues to occur in Egypt and is often associated with cardiac affection. The disease is enduring in impoverished urban regions in Egypt that are linked with underprivileged socioeconomic determinants and poorly ventilated premises. Misdiagnosis of ARF and its complications is noticeably common. This, together with poor compliance to BPG prophylaxis and poor living conditions, may affect efforts being exerted to eradicate the disease.

Children of RHD patients seem to have a higher predilection for ARF/RHD. Accordingly, we emphasize that suspicion of ARF/RHD should be heightened when there is a family history. Screening of family members of RHD patients is warranted if they reside in high-risk environments.

The messages that came from our experience have potentially important implications for echocardiography-based case finding and early detection, delivery of effective prevention, and adequate planning of health services.

Priority for action {#sec031}
-------------------

Sustained outreach RHD screening campaigns and school-based clinics employing echocardiography should be established in marginalized communities for the early detection of the disease.

Formulating national guidelines, enforcing a well-planned national strategy, upgrading the national registry system by employing REDCap (Research Electronic Data Capture), capacity building, increased access to echocardiography, strengthening the quality of BPG for better patient compliance, fostering research for new streptococcal vaccine candidates, and adopting appropriate investigations should be emphasized.
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